Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Marsha Moses, PH.D.

TitleJulia Dyckman Andrus Professor of Surgery
InstitutionChildren's Hospital Boston
DepartmentSurgery
AddressChildrens Hospital
Karp Family Research Laboratories, 12.129
300 Longwood Ave
Boston MA 02115
Phone6179192207
Fax617/730-4655

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Sreenivasan AK, Bachur CD, Lanier KE, Curatolo AS, Connors SM, Moses MA, Comi AM. Urine vascular biomarkers in Sturge-Weber syndrome. Vasc Med. 2013 Jun; 18(3):122-8.
    View in: PubMed
  2. Jia D, Hasso SM, Chan J, Filingeri D, D'Amore PA, Rice L, Pampo C, Siemann DW, Zurakowski D, Rodig SJ, Moses MA. Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood. 2013 Jan 24; 121(4):707-15.
    View in: PubMed
  3. Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin MA, D'Souza-Schorey C, Freeman MR. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 2012 Nov; 181(5):1573-84.
    View in: PubMed
  4. Yang J, McNeish B, Butterfield C, Moses MA. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J. 2013 Jan; 27(1):45-50.
    View in: PubMed
  5. Guo P, You JO, Yang J, Moses MA, Auguste DT. Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. Biomaterials. 2012 Nov; 33(32):8104-10.
    View in: PubMed
  6. Nikolova A, Ablasser K, Wyler von Ballmoos MC, Poutias D, Kaza E, McGowan FX, Moses MA, Del Nido PJ, Friehs I. Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy. Ann Thorac Surg. 2012 Nov; 94(5):1509-17.
    View in: PubMed
  7. Govindarajan B, Willoughby L, Band H, Curatolo AS, Veledar E, Chen S, Bonner MY, Abel MG, Moses MA, Arbiser JL. Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia. Vasc Cell. 2012; 4(1):11.
    View in: PubMed
  8. Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Oyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer. 2012; 12:169.
    View in: PubMed
  9. Cao Y, Arbiser J, D'Amato RJ, D'Amore PA, Ingber DE, Kerbel R, Klagsbrun M, Lim S, Moses MA, Zetter B, Dvorak H, Langer R. Forty-year journey of angiogenesis translational research. Sci Transl Med. 2011 Dec 21; 3(114):114rv3.
    View in: PubMed
  10. Roy R, Zurakowski D, Pories S, Moss ML, Moses MA. Potential of fluorescent metalloproteinase substrates for cancer detection. Clin Biochem. 2011 Dec; 44(17-18):1434-9.
    View in: PubMed
  11. Coticchia CM, Curatolo AS, Zurakowski D, Yang J, Daniels KE, Matulonis UA, Moses MA. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol. 2011 Nov; 123(2):295-300.
    View in: PubMed
  12. Harten IA, Zahr RS, Lemire JM, Machan JT, Moses MA, Doiron RJ, Curatolo AS, Rothman FG, Wight TN, Toole BP, Gordon LB. Age-dependent loss of MMP-3 in Hutchinson-Gilford progeria syndrome. J Gerontol A Biol Sci Med Sci. 2011 Nov; 66(11):1201-7.
    View in: PubMed
  13. Zhou B, Honor LB, He H, Ma Q, Oh JH, Butterfield C, Lin RZ, Melero-Martin JM, Dolmatova E, Duffy HS, Gise Av, Zhou P, Hu YW, Wang G, Zhang B, Wang L, Hall JL, Moses MA, McGowan FX, Pu WT. Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest. 2011 May; 121(5):1894-904.
    View in: PubMed
  14. Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses MA. ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasis. J Biol Chem. 2011 Jun 10; 286(23):20758-68.
    View in: PubMed
  15. Zhang B, Tsang PC, Pate JL, Moses MA. A role for cysteine-rich 61 in the angiogenic switch during the estrous cycle in cows: regulation by prostaglandin F2alpha. Biol Reprod. 2011 Aug; 85(2):261-8.
    View in: PubMed
  16. Roy R, Moses MA. ADAM12 induces estrogen-independence in breast cancer cells. Breast Cancer Res Treat. 2012 Feb; 131(3):731-41.
    View in: PubMed
  17. Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ, Moses MA. The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor. J Biol Chem. 2010 Dec 31; 285(53):41886-95.
    View in: PubMed
  18. Glasgow CG, Steagall WK, Taveira-Dasilva A, Pacheco-Rodriguez G, Cai X, El-Chemaly S, Moses M, Darling T, Moss J. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med. 2010 Jul; 104 Suppl 1:S45-58.
    View in: PubMed
  19. Nicksa GA, O'Neil E, Yu DC, Curatolo AS, McNeish BL, Barnewolt CE, Zurakowski D, Buchmiller TL, Moses MA, Rosen S, Fauza DO. Correlation between prenatal urinary matrix metalloproteinase activity and the degree of kidney damage in a large animal model of congenital obstructive uropathy. J Pediatr Surg. 2010 Jun; 45(6):1120-5.
    View in: PubMed
  20. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
    View in: PubMed
  21. Dudley AC, Udagawa T, Melero-Martin JM, Shih SC, Curatolo A, Moses MA, Klagsbrun M. Bone marrow is a reservoir for proangiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors. Blood. 2010 Oct 28; 116(17):3367-71.
    View in: PubMed
  22. Becker CM, Louis G, Exarhopoulos A, Mechsner S, Ebert AD, Zurakowski D, Moses MA. Matrix metalloproteinases are elevated in the urine of patients with endometriosis. Fertil Steril. 2010 Nov; 94(6):2343-6.
    View in: PubMed
  23. Novak KB, Le HD, Christison-Lagay ER, Nose V, Doiron RJ, Moses MA, Puder M. Effects of metalloproteinase inhibition in a murine model of renal ischemia-reperfusion injury. Pediatr Res. 2010 Mar; 67(3):257-62.
    View in: PubMed
  24. Sales VL, Mettler BA, Engelmayr GC, Aikawa E, Bischoff J, Martin DP, Exarhopoulos A, Moses MA, Schoen FJ, Sacks MS, Mayer JE. Endothelial progenitor cells as a sole source for ex vivo seeding of tissue-engineered heart valves. Tissue Eng Part A. 2010 Jan; 16(1):257-67.
    View in: PubMed
  25. Nicksa GA, Yu DC, Curatolo AS, McNeish BL, Barnewolt CE, Valim C, Buchmiller TL, Moses MA, Fauza DO. Prenatal urinary matrix metalloproteinase profiling as a potential diagnostic tool in fetal obstructive uropathy. J Pediatr Surg. 2010 Jan; 45(1):70-3.
    View in: PubMed
  26. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009 Nov 1; 27(31):5287-97.
    View in: PubMed
  27. Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle. 2009 Aug; 8(15):2347-52.
    View in: PubMed
  28. Chang SH, Kanasaki K, Gocheva V, Blum G, Harper J, Moses MA, Shih SC, Nagy JA, Joyce J, Bogyo M, Kalluri R, Dvorak HF. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009 May 15; 69(10):4537-44.
    View in: PubMed
  29. Lee PS, Tsang SW, Moses MA, Trayes-Gibson Z, Hsiao LL, Jensen R, Squillace R, Kwiatkowski DJ. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Am J Respir Cell Mol Biol. 2010 Feb; 42(2):227-34.
    View in: PubMed
  30. Manfredi MA, Fox VL, Zurakowski D, Kutok JL, Glickman JN, Moses MA. Matrix metalloproteinases in the urine and tissue of patients with juvenile polyps: potential biomarkers for the presence of polyps. J Pediatr Gastroenterol Nutr. 2009 Apr; 48(4):405-11.
    View in: PubMed
  31. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A. 2009 Mar 10; 106(10):3913-8.
    View in: PubMed
  32. Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, Zurakowski D, Moses MA. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 2008 Oct 15; 14(20):6610-7.
    View in: PubMed
  33. Coticchia CM, Yang J, Moses MA. Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw. 2008 Sep; 6(8):795-802.
    View in: PubMed
  34. Manfredi MA, Zurakowski D, Rufo PA, Walker TR, Fox VL, Moses MA. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008 Aug; 14(8):1091-6.
    View in: PubMed
  35. Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S, Exarhopoulos A, Scheib RG, Schumer S, Lenahan C, Borges V, Louis GW, Anand A, Isakovich N, Hirshfield-Bartek J, Wewer U, Lotz MM, Moses MA. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1034-42.
    View in: PubMed
  36. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008 Apr 15; 14(8):2378-86.
    View in: PubMed
  37. Klagsbrun M, Moses MA. Obituary: M. Judah Folkman (1933-2008). Nature. 2008 Feb 14; 451(7180):781.
    View in: PubMed
  38. Alwayn IP, Verbesey JE, Kim S, Roy R, Arsenault DA, Greene AK, Novak K, Laforme A, Lee S, Moses MA, Puder M. A critical role for matrix metalloproteinases in liver regeneration. J Surg Res. 2008 Apr; 145(2):192-8.
    View in: PubMed
  39. Rickert D, Franke RP, Lendlein A, Kelch S, Moses MA. Influence of the surface structure of a multiblock copolymer on the cellular behavior of primary cell cultures of the upper aerodigestive tract in vitro. J Biomed Mater Res A. 2007 Nov; 83(2):558-69.
    View in: PubMed
  40. Harper J, Yan L, Loureiro RM, Wu I, Fang J, D'Amore PA, Moses MA. Repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24. Cancer Res. 2007 Sep 15; 67(18):8736-41.
    View in: PubMed
  41. Ge G, Fernández CA, Moses MA, Greenspan DS. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proc Natl Acad Sci U S A. 2007 Jun 12; 104(24):10010-5.
    View in: PubMed
  42. Smith ER, Manfredi M, Scott RM, Black PM, Moses MA. A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery. 2007 Jun; 60(6):E1148-9; discussion E1149.
    View in: PubMed
  43. Rickert D, Franke RP, Fernández CA, Kilroy S, Yan L, Moses MA. Establishment and biochemical characterization of primary cells of the upper aerodigestive tract. Clin Hemorheol Microcirc. 2007; 36(1):47-64.
    View in: PubMed
  44. Alwayn IP, Andersson C, Lee S, Arsenault DA, Bistrian BR, Gura KM, Nose V, Zauscher B, Moses M, Puder M. Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. Am J Physiol Gastrointest Liver Physiol. 2006 Dec; 291(6):G1011-9.
    View in: PubMed
  45. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med. 2006 Jun 15; 354(24):2621-2.
    View in: PubMed
  46. Fernández CA, Moses MA. Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4. Biochem Biophys Res Commun. 2006 Jun 23; 345(1):523-9.
    View in: PubMed
  47. Vogel AM, Smithers CJ, Kozakewich HP, Zurakowski D, Moses MA, Burrows PE, Fauza DO, Fishman SJ. Extracellular matrix dynamics associated with tissue-engineered intravascular sclerotherapy. J Pediatr Surg. 2006 Apr; 41(4):757-62.
    View in: PubMed
  48. Greene AK, Puder M, Roy R, Arsenault D, Kwei S, Moses MA, Orgill DP. Microdeformational wound therapy: effects on angiogenesis and matrix metalloproteinases in chronic wounds of 3 debilitated patients. Ann Plast Surg. 2006 Apr; 56(4):418-22.
    View in: PubMed
  49. Rickert D, Lendlein A, Peters I, Moses MA, Franke RP. Biocompatibility testing of novel multifunctional polymeric biomaterials for tissue engineering applications in head and neck surgery: an overview. Eur Arch Otorhinolaryngol. 2006 Mar; 263(3):215-22.
    View in: PubMed
  50. Roy R, Zhang B, Moses MA. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res. 2006 Mar 10; 312(5):608-22.
    View in: PubMed
  51. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS. 2006; (96):223-68.
    View in: PubMed
  52. Friehs I, Margossian RE, Moran AM, Cao-Danh H, Moses MA, del Nido PJ. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res Cardiol. 2006 May; 101(3):204-13.
    View in: PubMed
  53. Benisty JI, Folkman J, Zurakowski D, Louis G, Rich S, Langleben D, Moses MA. Matrix metalloproteinases in the urine of patients with pulmonary arterial hypertension. Chest. 2005 Dec; 128(6 Suppl):572S.
    View in: PubMed
  54. Fernández CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005 Aug 1; 11(15):5390-5.
    View in: PubMed
  55. Marler JJ, Fishman SJ, Kilroy SM, Fang J, Upton J, Mulliken JB, Burrows PE, Zurakowski D, Folkman J, Moses MA. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics. 2005 Jul; 116(1):38-45.
    View in: PubMed
  56. Rickert D, Lendlein A, Kelch S, Franke RP, Moses MA. [Cell proliferation and cellular activity of primary cell cultures of the oral cavity after cell seeding on the surface of a degradable, thermoplastic block copolymer]. Biomed Tech (Berl). 2005 Apr; 50(4):92-9.
    View in: PubMed
  57. Zhang B, Yan L, Tsang PC, Moses MA. Matrix metalloproteinase-2 (MMP-2) expression and regulation by tumor necrosis factor alpha (TNFalpha) in the bovine corpus luteum. Mol Reprod Dev. 2005 Feb; 70(2):122-32.
    View in: PubMed
  58. Rickert D, Lendlein A, Kelch S, Moses MA, Franke RP. Expression of MMPs and TIMPs in primary epithelial cell cultures of the upper aerodigestive tract seeded on the surface of a novel polymeric biomaterial. Clin Hemorheol Microcirc. 2005; 32(2):117-28.
    View in: PubMed
  59. Shukla A, Dunn AR, Moses MA, Van Vliet KJ. Endothelial cells as mechanical transducers: enzymatic activity and network formation under cyclic strain. Mech Chem Biosyst. 2004 Dec; 1(4):279-90.
    View in: PubMed
  60. Greene AK, Puder M, Roy R, Kilroy S, Louis G, Folkman J, Moses MA. Urinary matrix metalloproteinases and their endogenous inhibitors predict hepatic regeneration after murine partial hepatectomy. Transplantation. 2004 Oct 27; 78(8):1139-44.
    View in: PubMed
  61. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem. 2004 Dec 3; 279(49):51323-30.
    View in: PubMed
  62. Chang LK, Garcia-Cardeña G, Farnebo F, Fannon M, Chen EJ, Butterfield C, Moses MA, Mulligan RC, Folkman J, Kaipainen A. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A. 2004 Aug 10; 101(32):11658-63.
    View in: PubMed
  63. Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Ménard C, Camphausen K. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol. 2004 Feb 1; 22(3):499-506.
    View in: PubMed
  64. Moses MA, Harper J, Fernández CA. A role for antiangiogenic therapy in breast cancer. Curr Oncol Rep. 2004 Jan; 6(1):42-8.
    View in: PubMed
  65. Munavalli G, Reisenauer A, Moses M, Kilroy S, Arbiser JL. Weight loss-induced calciphylaxis: potential role of matrix metalloproteinases. J Dermatol. 2003 Dec; 30(12):915-9.
    View in: PubMed
  66. Zhang B, Moses MA, Tsang PC. Temporal and spatial expression of tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1 and -2) in the bovine corpus luteum. Reprod Biol Endocrinol. 2003 Nov 7; 1:85.
    View in: PubMed
  67. Moses MA, Brem H, Langer R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell. 2003 Nov; 4(5):337-41.
    View in: PubMed
  68. Fernández CA, Butterfield C, Jackson G, Moses MA. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem. 2003 Oct 17; 278(42):40989-95.
    View in: PubMed
  69. Solan A, Mitchell S, Moses M, Niklason L. Effect of pulse rate on collagen deposition in the tissue-engineered blood vessel. Tissue Eng. 2003 Aug; 9(4):579-86.
    View in: PubMed
  70. Wu I, Moses MA. BNF-1, a novel gene encoding a putative extracellular matrix protein, is overexpressed in tumor tissues. Gene. 2003 Jun 5; 311:105-10.
    View in: PubMed
  71. Camphausen K, Moses MA, Ménard C, Sproull M, Beecken WD, Folkman J, O'Reilly MS. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 2003 Apr 15; 63(8):1990-3.
    View in: PubMed
  72. Govindarajan B, Bai X, Cohen C, Zhong H, Kilroy S, Louis G, Moses M, Arbiser JL. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem. 2003 Mar 14; 278(11):9790-5.
    View in: PubMed
  73. Rickert D, Moses MA, Lendlein A, Kelch S, Franke RP. The importance of angiogenesis in the interaction between polymeric biomaterials and surrounding tissue. Clin Hemorheol Microcirc. 2003; 28(3):175-81.
    View in: PubMed
  74. Moses MA, O'Reilly MS. Regulation of angiostatin mobilization by tumor-derived matrix metalloproteinase-2. Methods Mol Med. 2003; 74:375-90.
    View in: PubMed
  75. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002 Oct; 110(7):923-32.
    View in: PubMed
  76. Zhang B, Yan L, Moses MA, Tsang PC. Bovine membrane-type 1 matrix metalloproteinase: molecular cloning and expression in the corpus luteum. Biol Reprod. 2002 Jul; 67(1):99-106.
    View in: PubMed
  77. Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, Arnold RS, Lambeth JD. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A. 2002 Jan 22; 99(2):715-20.
    View in: PubMed
  78. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem. 2001 Oct 5; 276(40):37258-65.
    View in: PubMed
  79. Fang J, Yan L, Shing Y, Moses MA. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res. 2001 Aug 1; 61(15):5731-5.
    View in: PubMed
  80. Yan L, Moses MA. A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma. Am J Pathol. 2001 Apr; 158(4):1185-90.
    View in: PubMed
  81. Stock UA, Wiederschain D, Kilroy SM, Shum-Tim D, Khalil PN, Vacanti JP, Mayer JE, Moses MA. Dynamics of extracellular matrix production and turnover in tissue engineered cardiovascular structures. J Cell Biochem. 2001 Mar 26; 81(2):220-8.
    View in: PubMed
  82. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 2001 Mar 1; 61(5):2207-11.
    View in: PubMed
  83. Wu I, Moses MA. Cloning of a cDNA encoding an isoform of human protein phosphatase inhibitor 2 from vascularized breast tumor. DNA Seq. 2001; 11(6):515-8.
    View in: PubMed
  84. Stock UA, Sakamoto T, Hatsuoka S, Martin DP, Nagashima M, Moran AM, Moses MA, Khalil PN, Schoen FJ, Vacanti JP, Mayer JE. Patch augmentation of the pulmonary artery with bioabsorbable polymers and autologous cell seeding. J Thorac Cardiovasc Surg. 2000 Dec; 120(6):1158-67; discussion 1168.
    View in: PubMed
  85. LaMontagne KR, Moses MA, Wiederschain D, Mahajan S, Holden J, Ghazizadeh H, Frank DA, Arbiser JL. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol. 2000 Dec; 157(6):1937-45.
    View in: PubMed
  86. Yan L, Moses MA, Huang S, Ingber DE. Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells. J Cell Sci. 2000 Nov; 113 ( Pt 22):3979-87.
    View in: PubMed
  87. Wu I, Moses MA. Angiogenic molecules and mechanisms in breast cancer. Curr Oncol Rep. 2000 Nov; 2(6):566-71.
    View in: PubMed
  88. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):3884-9.
    View in: PubMed
  89. Scrivani SJ, Moses M, Donoff RB, Kaban LB. Taste perception after lingual nerve repair. J Oral Maxillofac Surg. 2000 Jan; 58(1):3-5; discussion 5-6.
    View in: PubMed
  90. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res. 1999 Dec 15; 59(24):6052-6.
    View in: PubMed
  91. Shum-Tim D, Stock U, Hrkach J, Shinoka T, Lien J, Moses MA, Stamp A, Taylor G, Moran AM, Landis W, Langer R, Vacanti JP, Mayer JE. Tissue engineering of autologous aorta using a new biodegradable polymer. Ann Thorac Surg. 1999 Dec; 68(6):2298-304; discussion 2305.
    View in: PubMed
  92. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem. 1999 Oct 8; 274(41):29568-71.
    View in: PubMed
  93. Gobet R, Bleakley J, Cisek L, Kaefer M, Moses MA, Fernandez CA, Peters CA. Fetal partial urethral obstruction causes renal fibrosis and is associated with proteolytic imbalance. J Urol. 1999 Sep; 162(3 Pt 1):854-60.
    View in: PubMed
  94. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol. 1999 Aug; 6(8):R217-24.
    View in: PubMed
  95. Kräling BM, Wiederschain DG, Boehm T, Rehn M, Mulliken JB, Moses MA. The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. J Cell Sci. 1999 May; 112 ( Pt 10):1599-609.
    View in: PubMed
  96. Moses MA, Wiederschain D, Wu I, Fernandez CA, Ghazizadeh V, Lane WS, Flynn E, Sytkowski A, Tao T, Langer R. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):2645-50.
    View in: PubMed
  97. Dethlefsen SM, Raab G, Moses MA, Adam RM, Klagsbrun M, Freeman MR. Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. J Cell Biochem. 1998 May 1; 69(2):143-53.
    View in: PubMed
  98. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998 Apr 1; 58(7):1395-9.
    View in: PubMed
  99. Wu I, Moses MA. Molecular cloning and expression analysis of the cDNA encoding rat tissue inhibitor of metalloproteinase-4. Matrix Biol. 1998 Jan; 16(6):339-42.
    View in: PubMed
  100. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem. 1997 Dec 12; 272(50):31730-7.
    View in: PubMed
  101. Peters CA, Freeman MR, Fernandez CA, Shepard J, Wiederschain DG, Moses MA. Dysregulated proteolytic balance as the basis of excess extracellular matrix in fibrotic disease. Am J Physiol. 1997 Jun; 272(6 Pt 2):R1960-5.
    View in: PubMed
  102. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M, Flynn E, Parangi S, Byers HR, Folkman J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A. 1997 Feb 4; 94(3):861-6.
    View in: PubMed
  103. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells. 1997; 15(3):180-9.
    View in: PubMed
  104. Huang SH, Adamis AP, Wiederschain DG, Shima DT, Shing Y, Moses MA. Matrix metalloproteinases and their inhibitors in aqueous humor. Exp Eye Res. 1996 May; 62(5):481-90.
    View in: PubMed
  105. Goldberg MJ, Moses MA, Tsang PC. Identification of matrix metalloproteinases and metalloproteinase inhibitors in bovine corpora lutea and their variation during the estrous cycle. J Anim Sci. 1996 Apr; 74(4):849-57.
    View in: PubMed
  106. Moses MA, Marikovsky M, Harper JW, Vogt P, Eriksson E, Klagsbrun M, Langer R. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J Cell Biochem. 1996 Mar 1; 60(3):379-86.
    View in: PubMed
  107. Wu I, Moses MA. Cloning and expression of the cDNA encoding rat tissue inhibitor of metalloproteinase 3 (TIMP-3). Gene. 1996 Feb 12; 168(2):243-6.
    View in: PubMed
  108. Moses MA, Klagsbrun M, Shing Y. The role of growth factors in vascular cell development and differentiation. Int Rev Cytol. 1995; 161:1-48.
    View in: PubMed
  109. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994 Oct 21; 79(2):315-28.
    View in: PubMed
  110. Rosenthal RA, Moses MA, Shintani Y, Megyesi JF, Langer R, Folkman J. Purification and characterization of two collagenase inhibitors from mouse sarcoma 180 conditioned medium. J Cell Biochem. 1994 Sep; 56(1):97-105.
    View in: PubMed
  111. Braunhut SJ, Moses MA. Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP). J Biol Chem. 1994 May 6; 269(18):13472-9.
    View in: PubMed
  112. Moses MA, Shing Y. Production of matrix metalloproteinases and a metalloproteinase inhibitor by swarm rat chondrosarcoma. Biochem Biophys Res Commun. 1994 Feb 28; 199(1):418-24.
    View in: PubMed
  113. Sasisekharan R, Moses MA, Nugent MA, Cooney CL, Langer R. Heparinase inhibits neovascularization. Proc Natl Acad Sci U S A. 1994 Feb 15; 91(4):1524-8.
    View in: PubMed
  114. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH, Folkman J. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol. 1994; 59:471-82.
    View in: PubMed
  115. Moses MA. A cartilage-derived inhibitor of neovascularization and metalloproteinases. Clin Exp Rheumatol. 1993 Mar-Apr; 11 Suppl 8:S67-9.
    View in: PubMed
  116. Moses MA, Sudhalter J, Langer R. Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol. 1992 Oct; 119(2):475-82.
    View in: PubMed
  117. Moses MA, Langer R. Metalloproteinase inhibition as a mechanism for the inhibition of angiogenesis. EXS. 1992; 61:146-51.
    View in: PubMed
  118. Moses MA, Langer R. A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem. 1991 Nov; 47(3):230-5.
    View in: PubMed
  119. Moses MA, Langer R. Inhibitors of angiogenesis. Biotechnology (N Y). 1991 Jul; 9(7):630-4.
    View in: PubMed
  120. Langer R, Moses M. Biocompatible controlled release polymers for delivery of polypeptides and growth factors. J Cell Biochem. 1991 Apr; 45(4):340-5.
    View in: PubMed
  121. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science. 1990 Jun 15; 248(4961):1408-10.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Moses's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_